CD274 and inflammatory breast carcinoma: Immune cell positivity for PD-L1 was seen in 42.9% of the IBC patients, which is higher than previous studies have reported in unselected patients with breast cancer (6.0%) [12] and in patients with TNBC (31.6%) [32].